Byondis BV

Byondis is a biopharmaceutical company based in Nijmegen, The Netherlands, that began its biopharmaceutical activities in 2007. It became a new biopharmaceutical subsidiary in 2012, became an independent company in November 2019, and rebranded as Byondis in April 2020. It is a subsidiary of the holding company Byondis Holding B.V. The company describes itself as an independent clinical stage fully integrated biopharmaceutical research and development company creating innovative targeted medicines for cancer, with a focus on antibody-drug conjugates (ADCs) and antibody-based therapeutics. Its pipeline includes wholly-owned ADC technology platforms and programs such as BYON4228, a mAb targeting the CD47-SIRPα axis, and BYON4413, an ADC directed against CD123.

Byondis started its biopharmaceutical activities in 2007. In 2012, the company became a new biopharmaceutical subsidiary and quickly built a promising pipeline of innovative research and development programs. After becoming an independent company in November 2019, the biopharmaceutical company rebranded itself as Byondis in April 2020. Byondis is a subsidiary of the holding company Byondis Holding B.V.

An independent clinical stage fully integrated biopharmaceutical research and development company creating innovative targeted medicines for cancer, focused on antibody-drug conjugates and antibody-based therapeutics.

• BYON4228

  A mAb from Byondis' next generation immuno-oncology (IO) program that targets and blocks the CD47-SIRPα axis, responsible for tumors' ability to escape from recognition and destruction by the immune system.

• BYON4413

  An ADC directed against the molecular target CD123 (interleukin-3 receptor alpha chain), which is expressed on many hemato-oncological malignancies.

1. 1Developing meaningful advances in cancer treatmentbyondis.com
2. 2Developing meaningful advances in cancer treatmentbyondis.com
3. 3Realizing the full potential of our science and technology tbyondis.com
4. 4Our Commitment to Sustainability | Byondisbyondis.com
5. 5Byondis Appoints Timo van den Berg as Senior Director, Immuno-Oncology R&Dprnewswire.com